New combo therapy aims to boost platelets in immune disorder

NCT ID NCT07700238

Not yet recruiting Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding romiplostim to standard prednisone treatment improves platelet counts in adults with previously untreated primary immune thrombocytopenia (ITP). Participants receive either romiplostim plus prednisone or prednisone alone. The study measures how many people achieve a durable platelet response and how long they stay off additional treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: romiplostim and predniso(lo)ne
What this could lead to: If successful, this combination could become a new standard first-line treatment for ITP, reducing the need for long-term steroids and improving platelet counts.
What could go wrong: This is an early-phase trial with a moderate size, so results may not confirm benefit. Risks include side effects from both drugs, such as infection or bone marrow changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura primary thrombocytopenia Purpura, Thrombocytopenic, Idiopathic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IMMUNE THROMBOCYTOPENIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.